Patrice Gill

This inventor holds 15 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Innate Tumor Immunity, Inc.. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrice Gill. Retrieved from https://idiyas.com/inventor/patrice-gill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 7.4

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Chateauguay, CA (2007 - 2008)
Levittown, NJ (US) (2015 - 2016)
Levittown, PA (US) (2012 - 2022)

Company Filing History:

11 out of 3,745

Bristol-Myers Squibb Compnay

patents

4 out of 21

Innate Tumor Immunity, Inc.

patents

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

NLRP3 Modulators

Anticancer Agents

Kinase Inhibitors

Fluoroalkyl Compounds

Benzodiazepinone Compounds

Tricyclic Compounds

Bromodomain Inhibitors

Thiazolyl Compounds

Imidazo-Fused Compounds

Substituted Benzodiazepinones

Prodrugs

5H-Pyrido Compounds

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338228 - NLRP3 modulators (2025-06-24),

2. 12187706 - NLRP3 modulators (2025-01-07),

3. 12171756 - NLRP3 modulators (2024-12-24),

4. 11344543 - NLRP3 modulators (2022-05-31),

5. 10174024 - 5H-pyrido[3,2-B]indole compounds as anticancer agents (2019-01-08),

6. 9751879 - Tricyclic compounds as anticancer agents (2017-09-05),

7. 9492460 - Carbazole compounds useful as bromodomain inhibitors (2016-11-15),

8. 9427442 - Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds (2016-08-30),

9. 9273014 - Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof (2016-03-01),

10. 9242940 - N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds (2016-01-26),

11. 9187434 - Substituted 1,5-benzodiazepinones compounds (2015-11-17),

12. 8999918 - Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof (2015-04-07),

13. 8148400 - Thiazolyl compounds useful as kinase inhibitors (2012-04-03),

14. 7456194 - [object Object] (2008-11-25),

15. 7176214 - Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same (2007-02-13),

Title: The Innovative Contributions of Patrice Gill

Introduction

Patrice Gill, an accomplished inventor based in Levittown, PA, has made significant strides in the field of medicinal chemistry. With a portfolio of 14 patents, Gill is primarily recognized for his groundbreaking work on NLRP3 modulators, which hold promise for the treatment of proliferative disorders, including cancer.

Latest Patents

Among Gill's latest patents are those related to NLRP3 modulators. These innovations provide unique compounds defined by Formula (I), which are designed to act as modulators of NLRP3. Such compounds have the potential to serve as effective medicaments in treating various forms of cancer in subjects, including humans. The detailed structure of these compounds is essential for their functionality and effectiveness in therapeutic applications.

Career Highlights

Gill's illustrious career includes pivotal roles at prominent companies such as Bristol-Myers Squibb Company and Innate Tumor Immunity, Inc. His work in these organizations has helped advance the understanding and treatment of cancer, demonstrating his commitment to pushing the boundaries of medical science through innovation.

Collaborations

Throughout his career, Gill has collaborated with notable professionals, including Ashvinikumar V. Gavai and Claude A. Quesnelle. These partnerships have been instrumental in enhancing research efforts and facilitating the development of pioneering solutions in the medical field.

Conclusion

In conclusion, Patrice Gill represents a remarkable figure in the realm of innovation and invention. His dedication to developing NLRP3 modulators showcases the impact that inventors can have on advancing medicine and improving patient outcomes. With his extensive patent portfolio and collaborative spirit, Gill continues to inspire future generations of innovators in the fight against cancer.

Profile summary based on public USPTO records.